MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections. For press release please click here.
21 July 2015
The voice of Scotland’s life sciences industries
Members’ area
21 July 2015
MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections. For press release please click here.